Hospital
Hocking Valley Community Hospital
Hocking Valley Community Hospital was paid $13.74M by Medicaid between Jan 2018 and Dec 2024, across 197 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 17% of everything it billed.
33Billing provider infoHOCKING VALLEY COMMUNITY HOSPITAL
LOGAN, OH 43138
LOGAN, OH 43138
33aNPI1295840007assigned 08/20/2006
33bProvider typeCritical Access Hospital
28Total paid$13.74M
24GClaims324,774
24DCodes billed197
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Ohio
Rank by total paid#3 of 26
Median peer was paid$5.33M
This provider vs. median2.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 37,609 | $1.16M | |
| 2019 | 37,768 | $1.05M | |
| 2020 | 31,952 | $1.22M | |
| 2021 | 38,108 | $1.43M | |
| 2022 | 38,777 | $1.73M | |
| 2023 | 79,002 | $3.42M | |
| 2024incomplete | 61,558 | $3.72M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 17% | 22,938 | 20,537 | $2.38M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 16,726 | 14,598 | $1.64M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 12% | 15,070 | 14,345 | $1.58M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.7% | 10,485 | 8,872 | $1.19M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.7% | 7,142 | 6,420 | $916K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.7% | 6,166 | 5,652 | $783K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 3.6% | 3,506 | 2,995 | $495K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.3% | 5,384 | 1,335 | $449K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.2% | 3,683 | 3,443 | $444K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 1,354 | 1,101 | $332K |
| 64635 | 2.0% | 840 | 559 | $273K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.8% | 2,641 | 937 | $251K |
185 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 715 | $241K |
| 64493 | 1.7% | 647 | $234K | |
| 76000 | 1.6% | 2,885 | $227K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 727 | $221K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.5% | 1,677 | $211K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 1,380 | $195K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.3% | 566 | $177K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.1% | 1,516 | $154K |
| 80053 | Comprehensive metabolic panel | <1% | 12,877 | $116K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 858 | $103K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 857 | $92K |
| 20610 | <1% | 512 | $62K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,573 | $51K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 596 | $51K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,585 | $46K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,658 | $41K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,389 | $40K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 18,564 | $39K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,755 | $32K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,398 | $31K |
| 97161 | <1% | 411 | $28K | |
| 87400 | <1% | 3,496 | $25K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 183 | $24K |
| 73630 | <1% | 731 | $22K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 23,687 | $21K |
| 80061 | Lipid panel | <1% | 1,401 | $20K |
| 84484 | <1% | 6,574 | $19K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 284 | $19K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 156 | $18K |
| 73562 | <1% | 535 | $18K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,323 | $17K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 122 | $15K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 284 | $15K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 699 | $14K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 84 | $14K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 5,681 | $14K |
| 80306 | <1% | 2,482 | $14K | |
| 73030 | <1% | 471 | $12K | |
| 73110 | <1% | 438 | $12K | |
| 84439 | <1% | 484 | $12K | |
| 73610 | <1% | 517 | $12K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,837 | $11K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,231 | $11K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 167 | $11K |
| 87088 | <1% | 3,917 | $11K | |
| 74018 | <1% | 204 | $10K | |
| 71250 | <1% | 99 | $10K | |
| 80348 | <1% | 1,140 | $10K | |
| 73130 | <1% | 558 | $9K | |
| 20552 | <1% | 78 | $8K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 285 | $7K |
| 82728 | <1% | 299 | $7K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 908 | $6K |
| 82607 | <1% | 265 | $6K | |
| 80362 | <1% | 1,136 | $6K | |
| 80076 | <1% | 886 | $5K | |
| 83735 | <1% | 6,307 | $5K | |
| 87430 | <1% | 7,391 | $5K | |
| 87070 | <1% | 354 | $5K | |
| 81001 | <1% | 8,783 | $5K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 19 | $4K |
| 94060 | <1% | 30 | $4K | |
| 64640 | <1% | 13 | $4K | |
| 64494 | <1% | 639 | $4K | |
| 83540 | <1% | 351 | $4K | |
| 80346 | <1% | 222 | $4K | |
| 86140 | <1% | 202 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 149 | $3K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 29 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,863 | $3K |
| 87077 | <1% | 844 | $3K | |
| J3490 | Unclassified drugs | <1% | 1,916 | $3K |
| 85610 | <1% | 5,072 | $3K | |
| 64454 | <1% | 27 | $3K | |
| 72100 | <1% | 108 | $3K | |
| 83992 | <1% | 651 | $3K | |
| 85027 | <1% | 1,055 | $2K | |
| 80324 | <1% | 651 | $2K | |
| 12001 | <1% | 13 | $2K | |
| 85007 | <1% | 835 | $2K | |
| 73502 | <1% | 58 | $2K | |
| 83550 | <1% | 193 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 149 | $2K |
| 87186 | <1% | 733 | $2K | |
| 80361 | <1% | 697 | $2K | |
| 83690 | <1% | 1,952 | $1K | |
| 85652 | <1% | 291 | $1K | |
| G0378 | Hospital observation service, per hour | <1% | 29 | $1K |
| 80365 | <1% | 679 | $1K | |
| 82570 | <1% | 118 | $1K | |
| 85730 | <1% | 4,534 | $1K | |
| 99205 | Prolong outpt/office vis | <1% | 22 | $1K |
| 81025 | <1% | 2,092 | $1K | |
| 80354 | <1% | 651 | $1K | |
| 80347 | <1% | 651 | $1K | |
| 80373 | <1% | 654 | $1K | |
| 80356 | <1% | 651 | $1K | |
| 80360 | <1% | 650 | $1K | |
| 80353 | <1% | 651 | $1K | |
| 80368 | <1% | 651 | $1K | |
| 80355 | <1% | 652 | $1K | |
| 80366 | <1% | 651 | $1K | |
| 80370 | <1% | 650 | $1K | |
| 80372 | <1% | 651 | $1K | |
| 80358 | <1% | 651 | $1K | |
| 80359 | <1% | 651 | $1K | |
| 64636 | <1% | 838 | $1K | |
| 72110 | <1% | 15 | $1K | |
| 80320 | <1% | 82 | $852.16 | |
| 86703 | <1% | 33 | $838.32 | |
| 83605 | <1% | 855 | $834.41 | |
| 83880 | <1% | 503 | $807.70 | |
| 73560 | <1% | 14 | $741.36 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 16 | $723.92 |
| 99156 | <1% | 431 | $713.70 | |
| 85379 | <1% | 477 | $711.19 | |
| 73080 | <1% | 33 | $700.96 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 53 | $638.77 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 237 | $623.84 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,666 | $596.93 |
| 80069 | <1% | 28 | $583.22 | |
| 82746 | <1% | 64 | $564.05 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 72 | $504.38 |
| 83970 | <1% | 16 | $498.83 | |
| 96376 | <1% | 428 | $469.99 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,431 | $395.15 |
| 80329 | <1% | 68 | $382.51 | |
| 87040 | <1% | 377 | $346.82 | |
| 86900 | <1% | 19 | $345.60 | |
| 83655 | <1% | 12 | $332.05 | |
| 82043 | <1% | 57 | $320.99 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 438 | $312.49 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 109 | $303.01 |
| 80377 | <1% | 33 | $236.19 | |
| 84403 | <1% | 14 | $232.18 | |
| 82565 | <1% | 17 | $202.73 | |
| 84702 | <1% | 14 | $180.61 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 148 | $176.53 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 627 | $144.50 |
| 87899 | <1% | 32 | $140.13 | |
| 94760 | <1% | 7,720 | $130.50 | |
| 84703 | <1% | 95 | $113.29 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,648 | $113.27 |
| 87420 | <1% | 21 | $112.58 | |
| 74022 | <1% | 14 | $107.84 | |
| 73090 | <1% | 14 | $94.35 | |
| 85018 | <1% | 14 | $75.57 | |
| 82550 | <1% | 100 | $59.69 | |
| 81003 | <1% | 140 | $57.85 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 981 | $54.89 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 132 | $42.89 |
| J2704 | Injection, propofol, 10 mg | <1% | 404 | $39.66 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,114 | $33.27 |
| 82800 | <1% | 30 | $31.84 | |
| 86901 | <1% | 20 | $26.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 109 | $17.51 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 385 | $12.51 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 170 | $8.75 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 35 | $6.08 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 14 | $3.48 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 180 | $3.01 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 108 | $2.63 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 60 | $2.18 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 33 | $2.16 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 105 | $1.39 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 15 | $1.30 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 40 | $1.30 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 56 | $0.65 |
| 76377 | 0% | 414 | $0.00 | |
| 82150 | 0% | 27 | $0.00 | |
| 94762 | 0% | 173 | $0.00 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 31 | $0.00 |
| 51798 | 0% | 13 | $0.00 | |
| 94761 | 0% | 36 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 42 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 33 | $0.00 |
| 36000 | 0% | 55 | $0.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 1,418 | $0.00 |
| 99152 | 0% | 81 | $0.00 | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | 0% | 13 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 54 | $0.00 |
| 76376 | 0% | 63 | $0.00 | |
| 51702 | 0% | 14 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 20 | $0.00 |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGROW, JULIE (CFO)
| Provider | Location | Paid |
|---|---|---|
| Hocking Valley Community Hospital | Logan, OH | $1.16M |
| Hocking Valley Community Hospital | Logan, OH | $872.96 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.